Advertisement

Keywords

Fatty Acid Amide Hydrolase Vanilloid Receptor TRPV1 Receptor Trigeminal Neuron Culture Dorsal Root Ganglion Neuron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pertwee RG, Ross RA (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66: 101–121PubMedCrossRefGoogle Scholar
  2. 2.
    Di Marzo V, Blumberg PM, Szallasi A (2002) Endovanilloid signaling in pain. Curr Opin Neurobiol 12: 372–379PubMedGoogle Scholar
  3. 3.
    Parolaro D, Massi P, Rubino T, Monti E (2002) Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids 66: 319–332PubMedCrossRefGoogle Scholar
  4. 4.
    Rice ASC, Farquhar-Smith WP, Nagy I (2002) Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 66: 243–256PubMedCrossRefGoogle Scholar
  5. 5.
    Walker JM, Huang SM (2002) Endocannabinoids in pain modulation. Prostaglandins Leukot Essent Fatty Acids 66: 235–242PubMedCrossRefGoogle Scholar
  6. 6.
    Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T (2002) Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 66: 377–391PubMedGoogle Scholar
  7. 7.
    Wiley JL, Martin BR (2002) Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem Phys Lipids 121: 57–63PubMedCrossRefGoogle Scholar
  8. 8.
    Di Marzo V, Bisogno T, De Petrocellis L (2001) Anandamide: some like it hot. Trends Pharmacol Sci 22: 346–349PubMedGoogle Scholar
  9. 9.
    Di Marzo V, Blumberg PM, Szallasi A (2002) Endovanilloid signaling in pain. Curr Opin Neurobiol 12: 372–379PubMedGoogle Scholar
  10. 10.
    Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ et al (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99: 8400–8405PubMedGoogle Scholar
  11. 11.
    Evans R, Scott RH, Ross RA (2004) Multiple actions of anandamide on neonatal rat cultured sensory neurones. Br J Pharmacol 141: 1223–1233PubMedCrossRefGoogle Scholar
  12. 12.
    Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452–457PubMedGoogle Scholar
  13. 13.
    Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, Chambers JK, Randall AD, Davis JB (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129: 227–230PubMedGoogle Scholar
  14. 14.
    Ross RA, Gibson TM, Brockie HC, Leslie M, Pashmi G, Craib SJ, Di Marzo V, Pertwee RG (2001) Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol 132: 631–640PubMedCrossRefGoogle Scholar
  15. 15.
    Craib SJ, Ellington HC, Pertwee RG, Ross RA (2001) A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig isolated bronchus. Br J Pharmacol 134: 30–37PubMedCrossRefGoogle Scholar
  16. 16.
    Ross RA (2003) Minireview: anandamide and vanilloid TRP1 receptors. Br J Pharmacol 140: 790–801PubMedCrossRefGoogle Scholar
  17. 17.
    Jennings EA, Vaughan CW, Roberts LA, Christie MJ ( 2003) The actions of anandamide on rat superficial medullary dorsal horn neurons in vitro. J Physiol 548: 121–129PubMedCrossRefGoogle Scholar
  18. 18.
    Ralevic V, Kendall DA, Randall MD, Smart D (2002) Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sci 71: 2577–2594PubMedCrossRefGoogle Scholar
  19. 19.
    Sprague J, Harrison C, Rowbotham DJ, Smart D, Lambert DG (2001) Temperature-dependent activation of recombinant rat vanilloid VR1 receptors expressed in Hek293 cells by capsaicin and anandamide. Eur J Pharmacol 423: 121–125PubMedCrossRefGoogle Scholar
  20. 20.
    Jerman JC, Gray J, Brough SJ, Ooi L, Owen D, Davis JB, Smart D (2002) Comparison of effects of anandamide at recombinant and endogenous rat vanilloid receptors. Br J Anaesthesia 89: 882–887Google Scholar
  21. 21.
    Andersson DA, Adner M, Hogestatt ED, Zygmunt PM (2002) Mechanisms underlying tissue selectivity of anandamide and other vanilloid receptor agonists. Mol Pharmacol 62: 705–713PubMedCrossRefGoogle Scholar
  22. 22.
    Roberts LA, Christie MJ, Connor M (2002) Anandamide is a partial agonist at native vanilloid receptors in acutely isolated mouse trigeminal sensory neurons. Br J Pharmacol 137: 421–428PubMedCrossRefGoogle Scholar
  23. 23.
    Jung J, Hwang SW, Kwak J, Lee SY, Kang CJ, Kim WB, Kim D, Oh U (1999) Capsaicin binds to the intracellular domain of the capsaicin-Activated Ion Channel. J Neurosci 19: 529–538PubMedGoogle Scholar
  24. 24.
    Jordt SE, Julius D (2002) Molecular basis for species specificity to ‘hot’ chili peppers. Cell 108: 421–430PubMedCrossRefGoogle Scholar
  25. 25.
    Hillard CJ, Jarrahian A (2003) Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol 140: 802–808PubMedCrossRefGoogle Scholar
  26. 26.
    Glaser S, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch D (2003) Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci USA 100: 4269–4274PubMedCrossRefGoogle Scholar
  27. 27.
    De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agro A, Di Marzo V (2001) The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 276: 12856–12863PubMedGoogle Scholar
  28. 28.
    Harrison S, De Petrocellis L, Trevisani M, Benvenuti F, Bifulco M, Geppetti P, Di Marzo V (2003) Capsaicin-like effects of N-arachidonoyl dopamine in the isolated guinea pig bronchi and urinary bladder. Eur J Pharmacol 475: 107–114PubMedCrossRefGoogle Scholar
  29. 29.
    Toth A, Kedei N, Wang Y, Blumberg PM (2003) Arachidonyl dopamine as a ligand for the vanilloid receptor VR1 of the rat. Life Sci 73: 487–498PubMedGoogle Scholar
  30. 30.
    Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98: 9371–9376PubMedCrossRefGoogle Scholar
  31. 31.
    Orliac ML, Peroni R, Celuch SM, Adler-Grachinsky E (2002) Potentiation of anandamide effects in mesenteric beds isolated from endotoxemic rats. J Pharmacol Exp Therap 304: 179–184Google Scholar
  32. 32.
    Tucker RC, Kagaya M, Page CP, Spina D (2001) The endogenous cannabinoid agonist, anandamide stimulates sensory nerves in guinea-pig Airways. Br J Pharmacol 132: 1127–1135PubMedCrossRefGoogle Scholar
  33. 33.
    Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM (2004) Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br J Pharmacol 14: 1118–1130Google Scholar
  34. 34.
    Olah Z, Karai L, Iadarola MJ (2001) Anandamide activates vanilloid receptor 1 (VR1) at acidic Ph in dorsal root ganglia neurons and cells ectopically expressing VR1. J Biol Chem 276: 31163–31170PubMedGoogle Scholar
  35. 35.
    Hwang SW, Hawoon C, Kwak J, Lee S-Y, Kang C-J, Jung J, Cho S, Min KH, Suh Y-G, Kim G, Oh U (2000) Direct activation of capsaicin receptors by products of lipoxygenase: endogenous capsaicin-like substances. Proc Natl Acad Sci USA 97: 6155–6160PubMedGoogle Scholar
  36. 36.
    Ahluwalia J, Yaqoob M, Urban L, Bevan S, Nagy I (2003) Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release. J Neurochem 84: 585–591PubMedCrossRefGoogle Scholar
  37. 37.
    Hermann H, De Petrocellis L, Bisogno T, Schiano Moriello A, Lutz B, Di Marzo V (2003) Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell Mol Life Sci 60: 607–616PubMedGoogle Scholar
  38. 38.
    Garcia DE, Brown S, Hille B, Mackie K (1998) Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J Neurosci 18: 2834–2841PubMedGoogle Scholar
  39. 39.
    Chuang HH, Prescott ED, Kong HY, Shields S, Jordt SE, Basbaum AI, Chao MV, Julius D (2001) Bradykinin and nerve growth factor release the capsaicin receptor from Ptdins(4,5)P-2-mediated inhibition. Nature 411: 957–962PubMedCrossRefGoogle Scholar
  40. 40.
    Netzeband JG, Conroy SM, Parsons KL, Gruol DL (1999) Cannabinoids enhance NMDA-elicited Ca2+ signals in cerebellar granule neurons in culture. J Neurosci 19: 8765–8777PubMedGoogle Scholar
  41. 41.
    Ho BY, Uezono Y, Takada S, Takase I, Izumi F (1999) Coupling of the expressed cannabinoid CB1 and CB2 receptors to phospholiase C and G-protein-coupled inwardly rectifying K+ channels. Receptors Channels 6: 363–374PubMedGoogle Scholar
  42. 42.
    Gomez Del Pulgar T, De Ceballos ML, Guzman M, Velasco G (2002) Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 277: 36527Google Scholar
  43. 43.
    Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I (2000) Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience 100: 685–688PubMedCrossRefGoogle Scholar
  44. 44.
    Ahluwalia J, Urban L, Bevan S, Capogna M, Nagy I (2002) Cannabinoid 1 receptors are expressed by nerve growth factor — and glial cell-derived neurotrophic factor-responsive primary sensory neurones. Neuroscience 110: 747–753PubMedCrossRefGoogle Scholar
  45. 45.
    Farquhar-Smith WP, Egertova M, Bradbury EJ, Mcmahon SB, Rice ASC, Elphick MR (2000) Cannabinoid CB1 receptor expression in rat spinal cord. Mol Cell Neurosci 15: 510–521PubMedCrossRefGoogle Scholar
  46. 46.
    Khasabova IA, Simone DA, Seybold VS (2002) Cannabinoids attenuate depolarizationdependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. Neuroscience 115: 613–625PubMedCrossRefGoogle Scholar
  47. 47.
    Bridges D, Rice ASC, Egertove M, Elphick MR, Winter J, Michael G (2003) Localisation of CB1 cannabinoid receptor in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience 119: 803–812PubMedCrossRefGoogle Scholar
  48. 48.
    Price TJ, Helesic G, Parghi D, Hargreaves KM, Flores CM (2003) The neuronal distribution of cannabinoid receptor type one in the trigeminal ganglion of the rat. Neuroscience 120: 155–162PubMedCrossRefGoogle Scholar
  49. 49.
    Khasabova IA, Harding-Rose C, Simone DA, Seybold VS (2004) Differential effects of CB1 and opioid agonists on two populations of adult rat dorsal root ganglion neurons. J Neurosci 24: 1744–1753PubMedCrossRefGoogle Scholar
  50. 50.
    Tognetto M, Amadesi S, Harrison S, Creminon C, Trevisani M, Carreras M, Matera M, Geppetti P, Bianchi A (2001) Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci 21 1104–1109PubMedGoogle Scholar
  51. 51.
    Ross RA, Coutts AA, Mcfarlane S, Irving AJ, Pertwee RG, Macewan DJ, Scott RH (2001) Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40: 221–232PubMedCrossRefGoogle Scholar
  52. 52.
    Ahluwalia J, Urban L, Bevan S, Nagy I (2003). Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Neuroscience 17: 2611–2618Google Scholar
  53. 53.
    Richardson JD, Kilo S, Hargreaves KM (1998) Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75: 111–119PubMedCrossRefGoogle Scholar
  54. 54.
    Mang CF, Erbelding D, Kilbinger H (2001) Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-Cb1 cannabinoid receptors. Br J Pharmacol 134: 161–167PubMedCrossRefGoogle Scholar
  55. 55.
    Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agro A (2000) Anandamide induces apoptosis in human cells via vanilloid receptors — evidence for a protective role of cannabinoid receptors. J Biol Chem 275: 31938–31945PubMedGoogle Scholar
  56. 56.
    Lever IJ, Malcangio M (2002) CB1 receptor antagonist SR141716A increases capsaicinevoked release of substance P from the adult mouse spinal cord. Br J Pharmacol 135: 21–24PubMedGoogle Scholar
  57. 57.
    Pertwee RG (2005) Inverse agonism and neutral antagonism at CB1 receptors. Life Sci 76: 1307–1324PubMedCrossRefGoogle Scholar
  58. 58.
    Ellington HC, Cotter MA, Cameron NE, Ross RA (2002) The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats. Neuropharmacology 42: 966–975PubMedCrossRefGoogle Scholar
  59. 59.
    Jia YL, Mcleod RL, Wang X, Parra LE, Egan RW, Hey JA (2002) Anandamide induces cough in conscious guinea-pigs through VR1 receptors. Br J Pharmacol 137: 831–836PubMedCrossRefGoogle Scholar
  60. 60.
    Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001) Evidence for a new G-protein coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60: 155–163PubMedGoogle Scholar
  61. 61.
    Sagan S, Venance L, Torrens Y, Cordier J, Glowinski J, Giaume C (1999) Anandamide and Win 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur J Neurosci 11: 691–699PubMedCrossRefGoogle Scholar
  62. 62.
    Offertaler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK, Martin BR, Bukoski RD, Kunos G (2003) Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63: 699–705PubMedCrossRefGoogle Scholar
  63. 63.
    Pertwee RG (2004) Novel targets for cannabinoids. Curr Neuropharm 2: 29Google Scholar
  64. 64.
    Zygmunt PM, Andersson DA, Hogestatt ED (2002) Δ9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 22: 4720–4727PubMedGoogle Scholar
  65. 65.
    Jordt SE, Bautista DM, Chuang HH, Mckemy DD, Zygmunt PM, Hogestatt ED, Meng ID, Julius D (2004) Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427: 260–265PubMedCrossRefGoogle Scholar
  66. 66.
    Kozak KR, Marnett LJ (2002) Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66: 211–220PubMedCrossRefGoogle Scholar
  67. 67.
    Compton DR, Martin BR (1997) The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect on anandamide in the mouse model of cannabimimetic activity. J Pharmacol Exp Ther 283: 1138–1143PubMedGoogle Scholar
  68. 68.
    Willoughby KA, Moore SF, Martin BR, Ellis EF (1997) The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 282: 243–247PubMedGoogle Scholar
  69. 69.
    Nilius B, Vriens J, Prenen J, Droogmans G, Voets T (2003) TRPV4 calcium entry channel: a paradigm for gating diversity. Am J Cell Physiol 286: C195–C205Google Scholar
  70. 70.
    Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B (2003) Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424: 434–439PubMedGoogle Scholar
  71. 71.
    Yu M, Ives D, Ramesha CS (1997) Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 272: 21181–21186PubMedGoogle Scholar
  72. 72.
    Burstein SH, Rossetti RG, Yagen B, Zurier RB (2000) Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat 61: 29–41PubMedGoogle Scholar
  73. 73.
    Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, Weinander R, Jakobsson PJ, Marnett LJ (2002) Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277: 44877–44885PubMedGoogle Scholar
  74. 74.
    Matias I, Chen J, De Petrocellis L, Bisogno T, Ligresti A, Fezza F, Krauss AHP, Shi L, Protzman Ce, Li C et al (2004) Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther 309: 745–757PubMedCrossRefGoogle Scholar
  75. 75.
    Smith JAM, Davis CL, Burgess GM (2000) Prostaglandin E2-induced sensitization of bradykinin-evoked responses in rat dorsal root ganglion neurons is mediated by cAMP-dependent protein kinase A. Eur J Neurosci 12: 3250–3258PubMedGoogle Scholar
  76. 76.
    Ross RA, Craib SJ, Stevenson LA, Pertwee RG, Henderson A, Toole J, Ellington HC (2002) Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol Exp Ther 301: 900–907PubMedCrossRefGoogle Scholar
  77. 77.
    Ueda N, Yamamoto K, Yamamoto S, Tokunaga T, Shirakawa E, Shinkai H, Ogawa M, Sato T, Kudo I, Inoue K et al (1995) Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochim Biophys Acta 1254: 127–134PubMedGoogle Scholar
  78. 78.
    Edgemond WS, Hillard CJ, Falck JR, Kearn CS, Campbell WB (1998) Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol 54: 180–188PubMedGoogle Scholar
  79. 79.
    Hwang SW, Hawoon C, Kwak J, Lee S-Y, Kang C-J, Jung J, Cho S, Min KH, Suh Y-G, Kim G, Oh U (2000) Direct activation of capsaicin receptors by products of lipoxygenase: endogenous capsaicin-like substances. Proc Natl Acad Sci USA 97: 6155–6160PubMedGoogle Scholar
  80. 80.
    Piomelli D (2001) The ligand that came from within. Trends Pharmacol Sci 22: 17–19PubMedCrossRefGoogle Scholar
  81. 81.
    Shin J, Cho H, Hwang SW, Jung J, Shin CY, Lee S-Y, Kim SH, Lee MG, Choi YH, Kim J et al (2002) Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia. Proc Natl Acad Sci USA 99: 10150–10155PubMedGoogle Scholar
  82. 82.
    Carr MJ, Kollarik M, Meeker SN, Undem BJ (2002) A role for Trpv1 in bradykinininduced excitation of vagal airway afferent nerve terminals. J Pharmacol Exp Ther 304: 1275–1279CrossRefGoogle Scholar
  83. 83.
    Veldhuis WB, Van Der Stelt M, Wadman MW, Van Zadelhoff G, Maccarrone M, Fezza F, Veldink GA, Vliegenthart JFG, Bar PR, Nicolay K, Di Marzo V (2003) Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J Neurosci 23: 4127–4133PubMedGoogle Scholar
  84. 84.
    Kagaya M, Lamb J, Robbins J, Page CP, Spina D (2002) Characterization of the anandamide induced depolarization of guinea-pig isolated vagus nerve. Br J Pharmacol 137: 39–48PubMedCrossRefGoogle Scholar
  85. 85.
    Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, Wilkie GD, Austin BJ, Patricelli MP, Cravatt BF (2000) Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 97: 5044–5049PubMedCrossRefGoogle Scholar
  86. 86.
    Van Der Stelt M, Van Kuik JA, Bari M, Van Zadelhoff G, Leeflang BR, Veldink GA, Finazzi-Agro A, Vliegenthart JFG, Maccarrone M (2002) Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. J Med Chem 45: 3709–3720PubMedGoogle Scholar
  87. 87.
    O’sullivan SE, Kendall DA, Randall MD (2004) Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (Nada). Br J Pharmacol 141: 803–812PubMedGoogle Scholar
  88. 88.
    Premkumar LS, Qi Zh, Van Buren J, Raisinghani M (2004) Enhancement of potency and efficacy of NADA by PKC-mediated phosphorylation of vanilloid receptor. J Neurophysiol 91: 1442–1449PubMedGoogle Scholar
  89. 89.
    De Petrocellis L, Orlando P, Di Marzo V (1995) Anandamide, an endogenous cannabinomimetic substance, modulates rat brain protein kinase C in vitro. Biochem Mol Biol Int 36: 1127–1133PubMedGoogle Scholar
  90. 90.
    Fowler CJ (2004) Oleamide: a member of the endocannabinoid family? Br J Pharmacol 141: 195–196PubMedCrossRefGoogle Scholar
  91. 91.
    Ahern GP (2003) Activation of TRPV1 by the satiety factor oleoylethanolamide. J Biol Chem 278: 30429–30434PubMedCrossRefGoogle Scholar
  92. 92.
    Smart D, Jonsson KO, Vandevoorde S, Lambert DM, Fowler CJ (2002) ‘Entourage’ effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br J Pharmacol 136: 452–458PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2005

Authors and Affiliations

  • Ruth A. Ross
    • 1
  1. 1.School of Medical Sciences, Institute of Medical SciencesUniversity of AberdeenForesterhill, AberdeenUK

Personalised recommendations